The point-of-care opioid testing market size is projected to be worth US$ 450.9 million in 2023. The market is likely to surpass US$ 725.1 million by 2033 at a CAGR of 4.9% during the forecast period. The market for point-of-care opioid testing has been experiencing substantial growth and is expected to continue expanding. The increasing prevalence of opioid abuse, the opioid crisis, and the need for immediate and accurate detection are the key drivers of this market growth. The market size is influenced by factors such as regional variations in opioid abuse rates, regulatory policies, and healthcare infrastructure.
Point-of-care opioid testing find applications in diverse settings, including emergency departments, addiction treatment centers, law enforcement agencies, workplace drug testing programs, and community outreach programs. The ability to conduct immediate on-site testing without the need for specialized laboratory equipment makes these kits highly valuable in scenarios where rapid decision-making is critical.
Other Drivers Propelling the Demand for Point-of-Care Opioid Testing Market include:
Challenges for Companies /Manufacturers in the Point-of-Care Opioid Testing Market:
Opportunities in the Point-of-Care Opioid Testing Market Industry:
Latest Trends in the Point-of-Care Opioid Testing Market:
| Attributes | Details |
|---|---|
| Point-of-Care Opioid Testing Market Size (2023) | US$ 450.9 million |
| Point-of-Care Opioid Testing Market Projected Size (2033) | US$ 725.1 million |
| Value CAGR (2023 to 2033) | 4.9% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
From 2017 to 2022, the global point-of-care opioid testing market experienced a CAGR of 3.9%, reaching a market size of US$ 450.9 million in 2023.
From 2017 to 2022, the global point-of-care opioid testing industry witnessed significant growth as advancements in testing technologies have significantly contributed to the historic growth of the market. The development of point-of-care testing with improved accuracy, sensitivity, and speed has facilitated rapid screening and early detection of opioid use. These technological advancements have enhanced the convenience and accessibility of testing, leading to increased adoption and market growth.
Future Forecast for Point-of-Care Opioid Testing Market Industry:
Looking ahead, the global point-of-care opioid testing market industry is expected to rise at a CAGR of 4.9% from 2023 to 2033. During the forecast period, the market size is expected to reach US$ 725.1 million by 2033.
The point-of-care opioid testing industry is expected to continue its growth trajectory from 2023 to 2033, driven by increasing emphasis on patient-centered care and remote monitoring, there will be a growing demand for convenient and accessible testing options that can be performed in the comfort of one's home. Home-based testing kits and connected devices will empower individuals to monitor their opioid use, promote self-management, and facilitate remote consultations with healthcare providers.
| Country | The United States |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 227.4 million |
| CAGR % 2023 to End of Forecast (2033) | 4.2% |
The point-of-care opioid testing industry in the United States is expected to reach a market size of US$ 227.4 million by 2033, expanding at a CAGR of 4.2%. The opioid crisis remains a significant driver of the point-of-care opioid testing market in the United States. The increasing prevalence of opioid misuse and addiction has prompted healthcare providers, policymakers, and stakeholders to prioritize interventions and strategies to combat the crisis. Point-of-care opioid testing plays a crucial role in identifying opioid use, enabling early intervention, and monitoring treatment progress.
| Country | The United Kingdom |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 32.0 million |
| CAGR % 2023 to End of Forecast (2033) | 4.3% |
The point-of-care opioid testing industry in the United Kingdom is expected to reach a market value of US$ 32.0 million, expanding at a CAGR of 4.3% during the forecast period. Recent advancements in testing technologies have influenced the point-of-care opioid testing market in the UK. These advancements include the development of more accurate, sensitive, and user-friendly testing devices. Point-of-care opioid testing technologies, such as immunoassays, oral fluid tests, and urine tests, have become more reliable and accessible, supporting wider adoption in various healthcare settings.
| Country | China |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 54.7 million |
| CAGR % 2023 to End of Forecast (2033) | 6.4% |
The point-of-care opioid testing industry in China is anticipated to reach a market size of US$ 54.7 million, moving at a CAGR of 6.4% during the forecast period. The Chinese government has implemented initiatives and policies to combat substance abuse and improve public health outcomes. These initiatives include strengthening regulations on opioid medications, establishing rehabilitation centers, and promoting the use of point-of-care opioid testing in healthcare facilities. Government support and policies have been crucial drivers for the adoption and growth of the point-of-care opioid testing market in China.
| Country | Japan |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 39.9 million |
| CAGR % 2023 to End of Forecast (2033) | 6.2% |
The point-of-care opioid testing industry in Japan is estimated to reach a market size of US$ 39.9 million by 2033, thriving at a CAGR of 6.2%. Japan has seen increased research and development efforts in the field of point-of-care opioid testing. Academic institutions, research organizations, and healthcare companies are investing in the development of innovative testing methodologies, biomarkers, and data analysis algorithms. This driver fosters continuous innovation, advancements in testing technologies, and the potential for personalized medicine approaches in opioid addiction management.
| Country | South Korea |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 45.4 million |
| CAGR % 2023 to End of Forecast (2033) | 6.0% |
The point-of-care opioid testing industry in South Korea is expected to reach a market size of US$ 45.4 million, expanding at a CAGR of 6.0% during the forecast period. The South Korean government has implemented stricter regulations and monitoring measures for opioid medications. These regulations aim to prevent misuse, addiction, and illegal distribution of opioids. The increased focus on monitoring drives the adoption of point-of-care opioid testing as a tool to ensure compliance with regulations and enhance patient safety.
Principal Consultant
Test strips are expected to dominate the point-of-care opioid testing industry with a CAGR of 4.7% from 2023 to 2033. Test strips are available for different sample types, including urine, saliva, and blood. Urine is the most commonly used sample type for point-of-care opioid testing due to its ease of collection and high concentration of detectable substances. Saliva and blood samples may also be used in certain situations, such as in clinical laboratory settings or for specific testing requirements.
Multi-panel drug test kits are expected to dominate the point-of-care opioid testing industry with a CAGR of 5.2% from 2023 to 2033. Multi-panel kits allow for simultaneous testing of multiple drugs within a single device. Each drug panel on the test kit contains specific reagents or antibodies that react with the targeted drugs or their metabolites. When the sample is applied to the kit, it flows through the different panels, and if any of the targeted drugs are present, corresponding lines or color changes appear on the test result window.
Blood sample are expected to dominate the point-of-care opioid testing industry with a CAGR of 4.9% from 2023 to 2033. Blood samples provide a higher level of sensitivity and specificity compared to urine and saliva samples. The concentration of opioids and their metabolites in blood is generally higher and offers a more accurate representation of recent drug use. This makes blood testing particularly valuable in cases where precise quantification and detection of specific opioid compounds are required.
Forensic Laboratories is expected to dominate the point-of-care opioid testing industry with a CAGR of 5.4% from 2023 to 2033. Forensic laboratories play a crucial role in confirming preliminary point-of-care test results. Point-of-care tests provide rapid screening but may have limitations in terms of sensitivity and specificity. Forensic laboratories perform confirmatory testing to validate the presence of opioids and determine the precise concentration or level of opioids in a sample. This information is essential for legal proceedings, workplace incidents, and clinical decision-making.
The point-of-care opioid testing market is fiercely competitive, with many companies fighting for market dominance. To stay ahead of the competition in such a circumstance, essential players must develop effective conjugates.
Key Strategies Used by the Participants
Companies are investing in research & development to deliver product that improve efficiency, dependability, and cost-effectiveness. Product innovation allows businesses to differentiate themselves from their competition while also catering to the changing demands of their clients.
Key industry leaders frequently develop strategic partnerships and collaborations with other companies in order to harness their strengths and increase their market reach. Companies might also gain access to new technology and markets through such agreements.
The point-of-care opioid testing market is expanding rapidly in emerging regions such as China and India. Key firms are enhancing their distribution networks and developing local manufacturing facilities to increase their presence in these areas.
Mergers and acquisitions are frequently used by key players in the point-of-care opioid testing industry to consolidate their market position, extend their product range, and gain access to new markets.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key Developments in the Point-of-care opioid testing Market:
The market is slated to attain US$ 725.1 million by 2033.
The growth potential of the point-of-care opioid testing market is 4.9% CAGR through 2033.
Widespread abuse of opioid and increasing efficiencies in the point-of-care opioid testing are propelling the market growth.
Avon Healthcare, Triveni Traders & Diagnostic Private Limited, and AdvaCare Pharma USA are the top market players.
Product development and expansion into emerging markets are key strategies consolidating the key players’ position.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Value Added Insights 4.1. Product Adoption / Usage Analysis 4.2. Product USP’s 4.3. Investment Feasibility Matrix 4.4. Brand Analysis 4.5. Value Chain Analysis 4.6. Regulatory Landscape 4.7. PESTEL Analysis 4.8. Porter’s Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure Outlook 5.1.3. Global Drug of Abuse Testing Market Overview 5.2. Forecast Factors - Relevance & Impact 5.2.1. Key Player’s Historic Growth 5.2.2. Diagnosis Rate (%) 5.2.3. Favourable Government Regulations 5.2.4. Rising Demand for Opioid Testing 5.2.5. Technological Advancement in Opioid Test Kits 5.2.6. Increasing Incidence of Drug Abuse 5.2.7. Frequency of Product Approvals 5.3. Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Volume (in Units) Analysis 2017 to 2022 and Forecast, 2023 to 2033 6.1. Historical Volume (in Units) Analysis, 2017 to 2022 6.2. Current and Future Volume (in Units) Projections, 2023 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 7. Global Market - Pricing Analysis 7.1. Regional Pricing Analysis By Product 7.2. Pricing Break-up 7.2.1. Manufacturer Level Pricing 7.2.2. Distributor Level Pricing 7.3. Global Average Pricing Analysis Benchmark 7.4. Pricing Assumptions 8. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 8.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022 8.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 8.2.1. Y-o-Y Growth Trend Analysis 8.2.2. Absolute $ Opportunity Analysis 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Product, 2017 to 2022 9.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Product, 2023 to 2033 9.3.1. Strips 9.3.2. Cassettes 9.3.3. Drug Test Dip Cards 9.4. Market Attractiveness Analysis By Product 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Modality 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Modality, 2017 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Modality, 2023 to 2033 10.3.1. Single Panel Drug Test Kits 10.3.2. Multi-panel Drug Test Kits 10.4. Market Attractiveness Analysis By Modality 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Sample 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By Sample, 2017 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Sample, 2023 to 2033 11.3.1. Saliva 11.3.2. Blood 11.3.3. Urine 11.3.4. Others 11.4. Market Attractiveness Analysis By Sample 12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Analysis By End User, 2017 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033 12.3.1. Hospitals 12.3.2. Diagnostics Laboratories 12.3.3. Forensic Laboratories 12.3.4. Home Care Settings 12.3.5. Others 12.4. Market Attractiveness Analysis By End User 13. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region 13.1. Introduction 13.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Region, 2017 to 2022 13.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Region, 2023 to 2033 13.3.1. North America 13.3.2. Latin America 13.3.3. Europe 13.3.4. South Asia 13.3.5. East Asia 13.3.6. Oceania 13.3.7. Middle East and Africa 13.4. Market Attractiveness Analysis By Region 14. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022 14.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. USA 14.3.1.2. Canada 14.3.2. By Product 14.3.3. By Modality 14.3.4. By Sample 14.3.5. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Product 14.4.3. By Modality 14.4.4. By Sample 14.4.5. By End User 14.5. Country Level Analysis & Forecast 14.5.1. USA Market Analysis 14.5.1.1. Introduction 14.5.1.2. Market Analysis and Forecast by Market Taxonomy 14.5.1.2.1. By Product 14.5.1.2.2. By Modality 14.5.1.2.3. By Sample 14.5.1.2.4. By End User 14.5.2. Canada Market Analysis 14.5.2.1. Introduction 14.5.2.2. Market Analysis and Forecast by Market Taxonomy 14.5.2.2.1. By Product 14.5.2.2.2. By Modality 14.5.2.2.3. By Sample 14.5.2.2.4. By End User 14.6. Market Trends 14.7. Key Market Participants - Intensity Mapping 14.8. Drivers and Restraints - Impact Analysis 15. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022 15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. Brazil 15.3.1.2. Mexico 15.3.1.3. Argentina 15.3.1.4. Rest of Latin America 15.3.2. By Product 15.3.3. By Modality 15.3.4. By Sample 15.3.5. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Product 15.4.3. By Modality 15.4.4. By Sample 15.4.5. By End User 15.5. Country Level Analysis & Forecast 15.5.1. Brazil Market Analysis 15.5.1.1. Introduction 15.5.1.2. Market Analysis and Forecast by Market Taxonomy 15.5.1.2.1. By Product 15.5.1.2.2. By Modality 15.5.1.2.3. By Sample 15.5.1.2.4. By End User 15.5.2. Mexico Market Analysis 15.5.2.1. Introduction 15.5.2.2. Market Analysis and Forecast by Market Taxonomy 15.5.2.2.1. By Product 15.5.2.2.2. By Modality 15.5.2.2.3. By Sample 15.5.2.2.4. By End User 15.5.3. Argentina Market Analysis 15.5.3.1. Introduction 15.5.3.2. Market Analysis and Forecast by Market Taxonomy 15.5.3.2.1. By Product 15.5.3.2.2. By Modality 15.5.3.2.3. By Sample 15.5.3.2.4. By End User 15.6. Market Trends 15.7. Key Market Participants - Intensity Mapping 15.8. Drivers and Restraints - Impact Analysis 16. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022 16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. Germany 16.3.1.2. France 16.3.1.3. Italy 16.3.1.4. UK 16.3.1.5. Spain 16.3.1.6. Russia 16.3.1.7. BENELUX 16.3.1.8. Rest of Europe 16.3.2. By Product 16.3.3. By Modality 16.3.4. By Sample 16.3.5. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Product 16.4.3. By Modality 16.4.4. By Sample 16.4.5. By End User 16.5. Country Level Analysis & Forecast 16.5.1. Germany Market Analysis 16.5.1.1. Introduction 16.5.1.2. Market Analysis and Forecast by Market Taxonomy 16.5.1.2.1. By Product 16.5.1.2.2. By Modality 16.5.1.2.3. By Sample 16.5.1.2.4. By End User 16.5.2. France Market Analysis 16.5.2.1. Introduction 16.5.2.2. Market Analysis and Forecast by Market Taxonomy 16.5.2.2.1. By Product 16.5.2.2.2. By Modality 16.5.2.2.3. By Sample 16.5.2.2.4. By End User 16.5.3. Italy Market Analysis 16.5.3.1. Introduction 16.5.3.2. Market Analysis and Forecast by Market Taxonomy 16.5.3.2.1. By Product 16.5.3.2.2. By Modality 16.5.3.2.3. By Sample 16.5.3.2.4. By End User 16.5.4. UK Market Analysis 16.5.4.1. Introduction 16.5.4.2. Market Analysis and Forecast by Market Taxonomy 16.5.4.2.1. By Product 16.5.4.2.2. By Modality 16.5.4.2.3. By Sample 16.5.4.2.4. By End User 16.5.5. Spain Market Analysis 16.5.5.1. Introduction 16.5.5.2. Market Analysis and Forecast by Market Taxonomy 16.5.5.2.1. By Product 16.5.5.2.2. By Modality 16.5.5.2.3. By Sample 16.5.5.2.4. By End User 16.5.6. Russia Market Analysis 16.5.6.1. Introduction 16.5.6.2. Market Analysis and Forecast by Market Taxonomy 16.5.6.2.1. By Product 16.5.6.2.2. By Modality 16.5.6.2.3. By Sample 16.5.6.2.4. By End User 16.5.7. BENELUX Market Analysis 16.5.7.1. Introduction 16.5.7.2. Market Analysis and Forecast by Market Taxonomy 16.5.7.2.1. By Product 16.5.7.2.2. By Modality 16.5.7.2.3. By Sample 16.5.7.2.4. By End User 16.6. Market Trends 16.7. Key Market Participants - Intensity Mapping 16.8. Drivers and Restraints - Impact Analysis 17. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022 17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. India 17.3.1.2. Thailand 17.3.1.3. Indonesia 17.3.1.4. Malaysia 17.3.1.5. Rest of South Asia 17.3.2. By Product 17.3.3. By Modality 17.3.4. By Sample 17.3.5. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Product 17.4.3. By Modality 17.4.4. By Sample 17.4.5. By End User 17.5. Country Level Analysis & Forecast 17.5.1. India Market Analysis 17.5.1.1. Introduction 17.5.1.2. Market Analysis and Forecast by Market Taxonomy 17.5.1.2.1. By Product 17.5.1.2.2. By Modality 17.5.1.2.3. By Sample 17.5.1.2.4. By End User 17.5.2. Thailand Market Analysis 17.5.2.1. Introduction 17.5.2.2. Market Analysis and Forecast by Market Taxonomy 17.5.2.2.1. By Product 17.5.2.2.2. By Modality 17.5.2.2.3. By Sample 17.5.2.2.4. By End User 17.5.3. Indonesia Market Analysis 17.5.3.1. Introduction 17.5.3.2. Market Analysis and Forecast by Market Taxonomy 17.5.3.2.1. By Product 17.5.3.2.2. By Modality 17.5.3.2.3. By Sample 17.5.3.2.4. By End User 17.5.4. Malaysia Market Analysis 17.5.4.1. Introduction 17.5.4.2. Market Analysis and Forecast by Market Taxonomy 17.5.4.2.1. By Product 17.5.4.2.2. By Modality 17.5.4.2.3. By Sample 17.5.4.2.4. By End User 17.6. Market Trends 17.7. Key Market Participants - Intensity Mapping 17.8. Drivers and Restraints - Impact Analysis 18. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022 18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. China 18.3.1.2. Japan 18.3.1.3. South Korea 18.3.2. By Product 18.3.3. By Modality 18.3.4. By Sample 18.3.5. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Product 18.4.3. By Modality 18.4.4. By Sample 18.4.5. By End User 18.5. Country Level Analysis & Forecast 18.5.1. China Market Analysis 18.5.1.1. Introduction 18.5.1.2. Market Analysis and Forecast by Market Taxonomy 18.5.1.2.1. By Product 18.5.1.2.2. By Modality 18.5.1.2.3. By Sample 18.5.1.2.4. By End User 18.5.2. Japan Market Analysis 18.5.2.1. Introduction 18.5.2.2. Market Analysis and Forecast by Market Taxonomy 18.5.2.2.1. By Product 18.5.2.2.2. By Modality 18.5.2.2.3. By Sample 18.5.2.2.4. By End User 18.5.3. South Korea Market Analysis 18.5.3.1. Introduction 18.5.3.2. Market Analysis and Forecast by Market Taxonomy 18.5.3.2.1. By Product 18.5.3.2.2. By Modality 18.5.3.2.3. By Sample 18.5.3.2.4. By End User 18.6. Market Trends 18.7. Key Market Participants - Intensity Mapping 18.8. Drivers and Restraints - Impact Analysis 19. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022 19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. Australia 19.3.1.2. New Zealand 19.3.2. By Product 19.3.3. By Modality 19.3.4. By Sample 19.3.5. By End User 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Product 19.4.3. By Modality 19.4.4. By Sample 19.4.5. By End User 19.5. Country Level Analysis & Forecast 19.5.1. Australia Market Analysis 19.5.1.1. Introduction 19.5.1.2. Market Analysis and Forecast by Market Taxonomy 19.5.1.2.1. By Product 19.5.1.2.2. By Modality 19.5.1.2.3. By Sample 19.5.1.2.4. By End User 19.5.2. New Zealand Market Analysis 19.5.2.1. Introduction 19.5.2.2. Market Analysis and Forecast by Market Taxonomy 19.5.2.2.1. By Product 19.5.2.2.2. By Modality 19.5.2.2.3. By Sample 19.5.2.2.4. By End User 19.6. Market Trends 19.7. Key Market Participants - Intensity Mapping 19.8. Drivers and Restraints - Impact Analysis 20. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033 20.1. Introduction 20.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022 20.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 20.3.1. By Country 20.3.1.1. GCC Countries 20.3.1.2. Türkiye 20.3.1.3. Northern Africa 20.3.1.4. South Africa 20.3.1.5. Rest of Middle East and Africa 20.3.2. By Product 20.3.3. By Modality 20.3.4. By Sample 20.3.5. By End User 20.4. Market Attractiveness Analysis 20.4.1. By Country 20.4.2. By Product 20.4.3. By Modality 20.4.4. By Sample 20.4.5. By End User 20.5. Country Level Analysis & Forecast 20.5.1. GCC Countries Market Analysis 20.5.1.1. Introduction 20.5.1.2. Market Analysis and Forecast by Market Taxonomy 20.5.1.2.1. By Product 20.5.1.2.2. By Modality 20.5.1.2.3. By Sample 20.5.1.2.4. By End User 20.5.2. Türkiye Market Analysis 20.5.2.1. Introduction 20.5.2.2. Market Analysis and Forecast by Market Taxonomy 20.5.2.2.1. By Product 20.5.2.2.2. By Modality 20.5.2.2.3. By Sample 20.5.2.2.4. By End User 20.5.3. Northern Africa Market Analysis 20.5.3.1. Introduction 20.5.3.2. Market Analysis and Forecast by Market Taxonomy 20.5.3.2.1. By Product 20.5.3.2.2. By Modality 20.5.3.2.3. By Sample 20.5.3.2.4. By End User 20.5.4. South Africa Market Analysis 20.5.4.1. Introduction 20.5.4.2. Market Analysis and Forecast by Market Taxonomy 20.5.4.2.1. By Product 20.5.4.2.2. By Modality 20.5.4.2.3. By Sample 20.5.4.2.4. By End User 20.6. Market Trends 20.7. Key Market Participants - Intensity Mapping 20.8. Drivers and Restraints - Impact Analysis 21. Market Structure Analysis 21.1. Market Analysis by Tier of Companies 21.2. Market Share Analysis of Top Players 21.3. Market Presence Analysis 22. Competition Analysis 22.1. Competition Dashboard 22.2. Branding and Promotional Strategies, By Key Players 22.3. Key Development Analysis 22.4. Competition Deep Dive 22.4.1. Avon Healthcare 22.4.1.1. Overview 22.4.1.2. Product Portfolio 22.4.1.3. Key Financials 22.4.1.4. Sales Footprint 22.4.1.5. SWOT Analysis 22.4.1.6. Strategy Overview 22.4.1.6.1. Marketing Strategy 22.4.1.6.2. Product Strategy 22.4.1.6.3. Channel Strategy 22.4.2. Triveni Traders & Diagnostic Private Limited 22.4.2.1. Overview 22.4.2.2. Product Portfolio 22.4.2.3. Key Financials 22.4.2.4. Sales Footprint 22.4.2.5. SWOT Analysis 22.4.2.6. Strategy Overview 22.4.2.6.1. Marketing Strategy 22.4.2.6.2. Product Strategy 22.4.2.6.3. Channel Strategy 22.4.3. AdvaCare Pharma USA 22.4.3.1. Overview 22.4.3.2. Product Portfolio 22.4.3.3. Key Financials 22.4.3.4. Sales Footprint 22.4.3.5. SWOT Analysis 22.4.3.6. Strategy Overview 22.4.3.6.1. Marketing Strategy 22.4.3.6.2. Product Strategy 22.4.3.6.3. Channel Strategy 22.4.4. BTNX Inc. 22.4.4.1. Overview 22.4.4.2. Product Portfolio 22.4.4.3. Key Financials 22.4.4.4. Sales Footprint 22.4.4.5. SWOT Analysis 22.4.4.6. Strategy Overview 22.4.4.6.1. Marketing Strategy 22.4.4.6.2. Product Strategy 22.4.4.6.3. Channel Strategy 22.4.5. Phamatech 22.4.5.1. Overview 22.4.5.2. Product Portfolio 22.4.5.3. Key Financials 22.4.5.4. Sales Footprint 22.4.5.5. SWOT Analysis 22.4.5.6. Strategy Overview 22.4.5.6.1. Marketing Strategy 22.4.5.6.2. Product Strategy 22.4.5.6.3. Channel Strategy 22.4.6. ADC 22.4.6.1. Overview 22.4.6.2. Product Portfolio 22.4.6.3. Key Financials 22.4.6.4. Sales Footprint 22.4.6.5. SWOT Analysis 22.4.6.6. Strategy Overview 22.4.6.6.1. Marketing Strategy 22.4.6.6.2. Product Strategy 22.4.6.6.3. Channel Strategy 22.4.7. Worldwide Medical Corporation 22.4.7.1. Overview 22.4.7.2. Product Portfolio 22.4.7.3. Key Financials 22.4.7.4. Sales Footprint 22.4.7.5. SWOT Analysis 22.4.7.6. Strategy Overview 22.4.7.6.1. Marketing Strategy 22.4.7.6.2. Product Strategy 22.4.7.6.3. Channel Strategy 22.4.8. Accu-Stat Diagnostics, Inc 22.4.8.1. Overview 22.4.8.2. Product Portfolio 22.4.8.3. Key Financials 22.4.8.4. Sales Footprint 22.4.8.5. SWOT Analysis 22.4.8.6. Strategy Overview 22.4.8.6.1. Marketing Strategy 22.4.8.6.2. Product Strategy 22.4.8.6.3. Channel Strategy 22.4.9. ACON Laboratories, Inc. 22.4.9.1. Overview 22.4.9.2. Product Portfolio 22.4.9.3. Key Financials 22.4.9.4. Sales Footprint 22.4.9.5. SWOT Analysis 22.4.9.6. Strategy Overview 22.4.9.6.1. Marketing Strategy 22.4.9.6.2. Product Strategy 22.4.9.6.3. Channel Strategy 22.4.10. Alere 22.4.10.1. Overview 22.4.10.2. Product Portfolio 22.4.10.3. Key Financials 22.4.10.4. Sales Footprint 22.4.10.5. SWOT Analysis 22.4.10.6. Strategy Overview 22.4.10.6.1. Marketing Strategy 22.4.10.6.2. Product Strategy 22.4.10.6.3. Channel Strategy 22.4.11. Innovacon, Inc. 22.4.11.1. Overview 22.4.11.2. Product Portfolio 22.4.11.3. Key Financials 22.4.11.4. Sales Footprint 22.4.11.5. SWOT Analysis 22.4.11.6. Strategy Overview 22.4.11.6.1. Marketing Strategy 22.4.11.6.2. Product Strategy 22.4.11.6.3. Channel Strategy 22.4.12. Amedica Biotech, Inc 22.4.12.1. Overview 22.4.12.2. Product Portfolio 22.4.12.3. Key Financials 22.4.12.4. Sales Footprint 22.4.12.5. SWOT Analysis 22.4.12.6. Strategy Overview 22.4.12.6.1. Marketing Strategy 22.4.12.6.2. Product Strategy 22.4.12.6.3. Channel Strategy 22.4.13. Branan Medical Corporation 22.4.13.1. Overview 22.4.13.2. Product Portfolio 22.4.13.3. Key Financials 22.4.13.4. Sales Footprint 22.4.13.5. SWOT Analysis 22.4.13.6. Strategy Overview 22.4.13.6.1. Marketing Strategy 22.4.13.6.2. Product Strategy 22.4.13.6.3. Channel Strategy 22.4.14. Biosite Inc 22.4.14.1. Overview 22.4.14.2. Product Portfolio 22.4.14.3. Key Financials 22.4.14.4. Sales Footprint 22.4.14.5. SWOT Analysis 22.4.14.6. Strategy Overview 22.4.14.6.1. Marketing Strategy 22.4.14.6.2. Product Strategy 22.4.14.6.3. Channel Strategy 22.4.15. UCP Biosciences, Inc 22.4.15.1. Overview 22.4.15.2. Product Portfolio 22.4.15.3. Key Financials 22.4.15.4. Sales Footprint 22.4.15.5. SWOT Analysis 22.4.15.6. Strategy Overview 22.4.15.6.1. Marketing Strategy 22.4.15.6.2. Product Strategy 22.4.15.6.3. Channel Strategy 22.4.16. TransMed Company 22.4.16.1. Overview 22.4.16.2. Product Portfolio 22.4.16.3. Key Financials 22.4.16.4. Sales Footprint 22.4.16.5. SWOT Analysis 22.4.16.6. Strategy Overview 22.4.16.6.1. Marketing Strategy 22.4.16.6.2. Product Strategy 22.4.16.6.3. Channel Strategy 22.4.17. Vitrosens Biotechnology 22.4.17.1. Overview 22.4.17.2. Product Portfolio 22.4.17.3. Key Financials 22.4.17.4. Sales Footprint 22.4.17.5. SWOT Analysis 22.4.17.6. Strategy Overview 22.4.17.6.1. Marketing Strategy 22.4.17.6.2. Product Strategy 22.4.17.6.3. Channel Strategy 22.4.18. Abbot 22.4.18.1. Overview 22.4.18.2. Product Portfolio 22.4.18.3. Key Financials 22.4.18.4. Sales Footprint 22.4.18.5. SWOT Analysis 22.4.18.6. Strategy Overview 22.4.18.6.1. Marketing Strategy 22.4.18.6.2. Product Strategy 22.4.18.6.3. Channel Strategy 22.4.19. clarity diagnostics 22.4.19.1. Overview 22.4.19.2. Product Portfolio 22.4.19.3. Key Financials 22.4.19.4. Sales Footprint 22.4.19.5. SWOT Analysis 22.4.19.6. Strategy Overview 22.4.19.6.1. Marketing Strategy 22.4.19.6.2. Product Strategy 22.4.19.6.3. Channel Strategy 22.4.20. Alcotec Company Limited 22.4.20.1. Overview 22.4.20.2. Product Portfolio 22.4.20.3. Key Financials 22.4.20.4. Sales Footprint 22.4.20.5. SWOT Analysis 22.4.20.6. Strategy Overview 22.4.20.6.1. Marketing Strategy 22.4.20.6.2. Product Strategy 22.4.20.6.3. Channel Strategy 23. Assumptions and Acronyms Used 24. Research Methodology
Explore Healthcare Insights
View Reports
Point-of-Care Opioid Testing Market
